Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation

Oren Pasvolsky; Liat Shargian; Uri Rozovski; Ofir Wolach; Ron Ram; Michael Y. Shapira; Batia Avni; Polina Stepensky; Moshe Israeli; Liat Vidal-Fisher; Ofer Shpilberg; Pia Raanani; Moshe Yeshurun

doi:10.1080/10428194.2021.1929957

Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation

Oren Pasvolsky
, Liat Shargian
, Uri Rozovski
, Ofir Wolach
, Ron Ram
, Michael Y. Shapira
, Batia Avni
, Polina Stepensky
, Moshe Israeli
, Liat Vidal-Fisher
, Ofer Shpilberg
, Pia Raanani
, Moshe Yeshurun^*

^*Corresponding author for this work

Institute for Medical Research Israel-Canada (IMRIC)

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Platelet recovery after allogeneic umbilical cord blood (UCB) transplantation is delayed compared to other graft sources. We conducted a multicenter phase 2a study to explore whether eltrombopag, a thrombopoietin-receptor agonist, would enhance platelet recovery after UCB transplantation. Between 02/2013 and 07/2016, 12 (10 adults, 2 children) individuals (median age 50; range 6–74 years) with hematological malignancies in complete remission were enrolled. Eltrombopag was given for a median of 76 (range 15–175) days and was safe even at doses of 300 mg/day. Median time to neutrophil engraftment was 23 (range 16–40) days. Median time to platelets >20,000/µl and >50,000/µl was 55 (range 25–199) and 66 (range 31–230) days, respectively. A historical cohort comparison did not reveal an advantage for eltrombopag. In conclusion, in the present study eltrombopag seems safe. Based on our limited data, it seems unlikely that eltrombopag could enhance platelet engraftment after UCB transplantation.

Original language	English
Pages (from-to)	2747-2754
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	62
Issue number	11
DOIs	https://doi.org/10.1080/10428194.2021.1929957
State	Published - 2021

Bibliographical note

Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

Eltrombopag
allogeneic hematopoietic cell transplantation
platelet engraftment
umbilical cord blood

Access to Document

10.1080/10428194.2021.1929957

Cite this

Pasvolsky, O., Shargian, L., Rozovski, U., Wolach, O., Ram, R., Shapira, M. Y., Avni, B., Stepensky, P., Israeli, M., Vidal-Fisher, L., Shpilberg, O., Raanani, P., & Yeshurun, M. (2021). Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. Leukemia and Lymphoma, 62(11), 2747-2754. https://doi.org/10.1080/10428194.2021.1929957

@article{50c86a2c5d424d21951b109e3d730339,

title = "Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation",

abstract = "Platelet recovery after allogeneic umbilical cord blood (UCB) transplantation is delayed compared to other graft sources. We conducted a multicenter phase 2a study to explore whether eltrombopag, a thrombopoietin-receptor agonist, would enhance platelet recovery after UCB transplantation. Between 02/2013 and 07/2016, 12 (10 adults, 2 children) individuals (median age 50; range 6–74 years) with hematological malignancies in complete remission were enrolled. Eltrombopag was given for a median of 76 (range 15–175) days and was safe even at doses of 300 mg/day. Median time to neutrophil engraftment was 23 (range 16–40) days. Median time to platelets >20,000/µl and >50,000/µl was 55 (range 25–199) and 66 (range 31–230) days, respectively. A historical cohort comparison did not reveal an advantage for eltrombopag. In conclusion, in the present study eltrombopag seems safe. Based on our limited data, it seems unlikely that eltrombopag could enhance platelet engraftment after UCB transplantation.",

keywords = "Eltrombopag, allogeneic hematopoietic cell transplantation, platelet engraftment, umbilical cord blood",

author = "Oren Pasvolsky and Liat Shargian and Uri Rozovski and Ofir Wolach and Ron Ram and Shapira, \{Michael Y.\} and Batia Avni and Polina Stepensky and Moshe Israeli and Liat Vidal-Fisher and Ofer Shpilberg and Pia Raanani and Moshe Yeshurun",

note = "Publisher Copyright: {\textcopyright} 2021 Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2021",

doi = "10.1080/10428194.2021.1929957",

language = "אנגלית",

volume = "62",

pages = "2747--2754",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

Pasvolsky, O, Shargian, L, Rozovski, U, Wolach, O, Ram, R, Shapira, MY, Avni, B, Stepensky, P, Israeli, M, Vidal-Fisher, L, Shpilberg, O, Raanani, P & Yeshurun, M 2021, 'Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation', Leukemia and Lymphoma, vol. 62, no. 11, pp. 2747-2754. https://doi.org/10.1080/10428194.2021.1929957

TY - JOUR

T1 - Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation

AU - Pasvolsky, Oren

AU - Shargian, Liat

AU - Rozovski, Uri

AU - Wolach, Ofir

AU - Ram, Ron

AU - Shapira, Michael Y.

AU - Avni, Batia

AU - Stepensky, Polina

AU - Israeli, Moshe

AU - Vidal-Fisher, Liat

AU - Shpilberg, Ofer

AU - Raanani, Pia

AU - Yeshurun, Moshe

PY - 2021

Y1 - 2021

N2 - Platelet recovery after allogeneic umbilical cord blood (UCB) transplantation is delayed compared to other graft sources. We conducted a multicenter phase 2a study to explore whether eltrombopag, a thrombopoietin-receptor agonist, would enhance platelet recovery after UCB transplantation. Between 02/2013 and 07/2016, 12 (10 adults, 2 children) individuals (median age 50; range 6–74 years) with hematological malignancies in complete remission were enrolled. Eltrombopag was given for a median of 76 (range 15–175) days and was safe even at doses of 300 mg/day. Median time to neutrophil engraftment was 23 (range 16–40) days. Median time to platelets >20,000/µl and >50,000/µl was 55 (range 25–199) and 66 (range 31–230) days, respectively. A historical cohort comparison did not reveal an advantage for eltrombopag. In conclusion, in the present study eltrombopag seems safe. Based on our limited data, it seems unlikely that eltrombopag could enhance platelet engraftment after UCB transplantation.

AB - Platelet recovery after allogeneic umbilical cord blood (UCB) transplantation is delayed compared to other graft sources. We conducted a multicenter phase 2a study to explore whether eltrombopag, a thrombopoietin-receptor agonist, would enhance platelet recovery after UCB transplantation. Between 02/2013 and 07/2016, 12 (10 adults, 2 children) individuals (median age 50; range 6–74 years) with hematological malignancies in complete remission were enrolled. Eltrombopag was given for a median of 76 (range 15–175) days and was safe even at doses of 300 mg/day. Median time to neutrophil engraftment was 23 (range 16–40) days. Median time to platelets >20,000/µl and >50,000/µl was 55 (range 25–199) and 66 (range 31–230) days, respectively. A historical cohort comparison did not reveal an advantage for eltrombopag. In conclusion, in the present study eltrombopag seems safe. Based on our limited data, it seems unlikely that eltrombopag could enhance platelet engraftment after UCB transplantation.

KW - Eltrombopag

KW - allogeneic hematopoietic cell transplantation

KW - platelet engraftment

KW - umbilical cord blood

UR - https://www.scopus.com/pages/publications/85106310796

U2 - 10.1080/10428194.2021.1929957

DO - 10.1080/10428194.2021.1929957

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 34013829

AN - SCOPUS:85106310796

SN - 1042-8194

VL - 62

SP - 2747

EP - 2754

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -

Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this